AbbVie Aktie News

Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, policy uncertainties around drug pricing, and a surge in tech-driven gains from the AI boom.

Eli Lilly's GLP-1 drug became the world's best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other companies are soaring on new drugs or the growth of existing ones.

AbbVie is a Dividend King that has proven its resilience. Ares Capital offers an ultra-high yield, with solid near-term and long-term growth prospects.

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics' Role in ABBV-230 Development While Preserving AbbVie's Long-Term Commitment NANTES, France, December 8 th , 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced an amendment to its partnership agreemen...

I see a generational opportunity in quality stocks, defined by high ROE, stable earnings growth, and low debt. Quality stocks have underperformed AI-driven leaders, creating rare relative value and attractive risk/reward for diversified, income-focused investors. My screen highlights 33 U.S. large caps with ≥25% ROE and ≥2% yield, many trading at compelling valuations.

AbbVie's third-quarter results exceeded Wall Street's expectations. Sales from the pharmaceutical company's three top drugs are soaring.

AbbVie has performed exceedingly well over the past 12 years. The company still has many of the traits that led to that result.

AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript